Publication: Abilene Reporter-News, Abilene, TX
Dr. Anton Melnyk of Texas Oncology–Abilene discusses his participation in a clinical trial for the recently-approved immunotherapy drug Opdivo and the importance of research to extend lives in those with non-small cell lung cancer. Dr. Melnyk also explains the importance of prevention and living a healthy lifestyle.
Read the full story at Abilene Reporter-News, Abilene.